ETH Zurich scientists have engineered a light-controlled molecular switch that selectively destroys stress hormone receptors in dormant cancer cells, potentially reawakening them to treatment sensitivity. The preclinical lung cancer study demonstrates a new optogenetic strategy to overcome one of oncology's biggest therapeutic challenges: cancer cell dormancy and treatment resistance. โ Photo by Dฦฐฦกng Nhรขn on Pexels (Pexels License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accrรฉditation Sans Frontiรจres (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016โ2021). ORCID: 0000-0001-7609-4515.
